A carregar...
Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study
RATIONALE: Unlike many other COPD studies, the 4-year UPLIFT trial permitted inhaled corticosteroid (ICS) use during run-in and treatment phases. This provided the opportunity to prospectively observe the continuing effects of ICS on respiratory events in closely observed COPD population. OBJECTIVES...
Na minha lista:
Publicado no: | Lung |
---|---|
Main Authors: | , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Springer US
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5437199/ https://ncbi.nlm.nih.gov/pubmed/28255905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00408-017-9990-8 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|